Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/37128
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Pharmacokinetics of high-dose buprenorphine following single administration of sublingual tablet formulations in opioid naive healthy male volunteers under a naltrexone block
Author: McAleer, S.
Mills, R.
Polack, R.
Hussain, T.
Rolan, P.
Gibbs, A.
Mullins, F.
Hussein, F.
Citation: Drug and Alcohol Dependence, 2003; 72(1):75-83
Publisher: Elsevier Sci Ireland Ltd
Issue Date: 2003
ISSN: 0376-8716
Statement of
Responsibility: 
Sarah D. McAleer, Richard J. Mills, Torsten Polack, Tanweer Hussain, Paul E. Rolan, Alan D. Gibbs, Frank G. P. Mullins and Ziad Hussein
Abstract: Sublingual buprenorphine formulations have been developed as treatments for opioid dependence. In three studies, opioid naïve healthy male subjects received Subutex® tablets (buprenorphine 2 and 8 mg [N=27] or 12 and 16 mg [N=27]) or Suboxone® (two formulations) tablets (buprenorphine 8 mg/naloxone 2 mg [N=36]) sublingually, under a naltrexone block for assessment of buprenorphine pharmacokinetics and tablet disintegration times. Plasma buprenorphine was quantified up to 72 h post-dose using a sensitive LC–MS/MS assay. Mean Cmax values ranged from 1.6 to 6.4 ng/ml and tmax from 0.5 to 3 h. Concentrations declined bi-exponentially and fluctuations after a meal suggested enterohepatic recirculation of buprenorphine. The terminal half-life was approximately 26 h (range 9–69). Cmax and AUC appeared to increase in proportion to Subutex® dose over 8–16 mg. The Suboxone® formulations were bioequivalent. The least squares mean (90% CI) treatment ratio for Cmax was 1.00 (0.92–1.10) and AUC was 1.00 (0.95–1.06). Median times of disintegration were similar for all doses and formulations (range 6–12 min). Sublingual buprenorphine, up to 40 times the 400 μg analgesic dose, was well tolerated in these opioid naïve subjects, as administration of naltrexone 50–150 mg was sufficient to attenuate anticipated adverse effects in this population of subjects.
Keywords: Buprenorphine; sublingual; pharmacokinetics; volunteers; Naltrexone
RMID: 0020065990
DOI: 10.1016/S0376-8716(03)00188-1
Description (link): http://www.elsevier.com/wps/find/journaldescription.cws_home/506052/description#description
Appears in Collections:Pharmacology publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.